HemaXellerate I

HemaXellerate I is a personalized, autologous, adipose‑derived cellular therapy being developed by Regen BioPharma to stimulate bone marrow regeneration and restore hematopoiesis in patients with bone marrow failure syndromes such as aplastic anemia and chemotherapy‑induced myelosuppression.[6][12][13] The product is manufactured from cells extracted from the patient’s own fat tissue and processed using a proprietary method to induce a biological state that promotes recovery of hematopoietic stem cells and the bone marrow microenvironment, thereby enhancing production of erythrocytes, leukocytes, and platelets across all three major blood cell lineages.[6][12] Positioned as a novel supportive care and regenerative medicine approach, HemaXellerate I has FDA clearance to proceed to early‑phase clinical trials and is the subject of an orphan drug application in aplastic anemia, with potential expansion into broader oncology indications involving bone marrow suppression.[2][6][10][13]

Brand names

HemaXellerate IHemaXellerate